Clinical: serum CA 15-3, CA125, family history of BC, body mass index (BMI), carcinoembryonic antigen (CEA) levels.Pathological: ER, PR, HER2 status, Ki67, Lymphovascular invasion (LVI), and AR.Radiomics: TTP, tumor volume, and maximum tumor diameter. This evidence concerns the gene CEACAM5 and neoplasm.